Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
A lawsuit was filed for certain investors in Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares. Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and conti
April 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NTLA
07:15am, Monday, 03'rd Mar 2025
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal secu
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Th
NEW YORK , March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal secu
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal secu
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Intellia Therapeutics, Inc.
11:00am, Sunday, 02'nd Mar 2025
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc.
Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress
09:30am, Sunday, 02'nd Mar 2025
Intellia Therapeutics' stock is downgraded to HOLD due to market skepticism and lack of near-term catalysts despite promising Phase 3 trials for HAE and ATTR. NTLA-2002, Intellia's CRISPR/Cas9 drug fo
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal secu
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Th
Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NTLA
06:01pm, Saturday, 01'st Mar 2025
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal secu
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ:NTLA) between July 30,
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc.
NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA).
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
02:25pm, Friday, 28'th Feb 2025
Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.
